Skip to main content

Akebia Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

AKBA$0.53+32.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 9B. Other Information

Rule 10b5-1 - Director and Officer Trading Arrangements

From time to time, the Company's directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, engage in open-market transactions with respect to Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in Company securities by directors and officers are required to be made in accordance with the Company’s insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in the Company’s securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.

The following table describes, for the fourth quarter of 2023, each trading arrangement for the sale or purchase of Company securities adopted orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

Name (Title)Action Taken (Date of Action)Type of Trading ArrangementNature of Trading ArrangementDuration of Trading ArrangementAggregate Number of Securities
John P. Butler (President and Chief Executive Officer)December 1, 2023Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be grantedSaleUntil final settlement of any RSUsIndeterminable (1)
Ellen Snow (Senior Vice President, Chief Financial Officer and Treasurer)November 20, 2023Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be grantedSaleUntil final settlement of any RSUsIndeterminable (1)
Steven K. Burke, M.D. (Senior Vice President, Research & Development and Chief Medical Officer)November 17, 2023Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be grantedSaleUntil final settlement of any RSUsIndeterminable (1)
Michel Dahan (Senior Vice President, Chief Operating Officer)December 3, 2023Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be grantedSaleUntil final settlement of any RSUsIndeterminable (1)
Nicole R. Hadas (Senior Vice President, Chief Legal Officer and Corporate Secretary)November 14, 2023Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be grantedSaleUntil final settlement of any RSUsIndeterminable (1)

(1) The number of shares subject to RSUs that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement. This trading arrangement, which applies to RSUs whether vesting is based on the passage of time and/or the achievement of performance goals, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a RSU in an amount sufficient to satisfy the applicable tax withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable tax withholding obligation.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.